Endocrine Abstracts

Aim: The assessment of the disease course and selected clinicopathological factors associated with recurrence risk and the effectiveness of surgical treatment of PTC patients.Material and Methods: The retrospective analysis of 260 PTC patients selected from 403 patients operated on for recurrent thyroid cancer between 2002 and 2018 was performed. All statistical analyses were done using the programming environment R (v. 4.0.2).Resu...

Introduction: Reoperation due to recurrent or persistent thyroid cancer (TC) poses a real challenge to a surgeon who must properly estimate the benefit risk-ratio. Radioguided occult lesion localization (ROLL) technique may facilitate the localization and sufficient and safe removal of nonpalpable TC relapse.Aim: To analyze the efficacy of the ROLL technique in reoperation of TC relapse.Material and methods: A retrospective study o...

A global TC risk in a single thyroid nodule is rather small and ranges between 1 and 11%. However, taking into consideration Bethesda System for Reporting Thyroid Cytopathology TC risk varies between distinct categories: 0–3, 5–15, 15–30, 60–75 and 97–99% for Bethesda class II–VI, respectively. However, these values may differ in a centre, specialized in TC. Therefore, the aim of this study was to evaluate the TC risk in patients referred to a ter...

Objectives: Recent studies on BRAFV600E mutation, known as initiating event in papillary thyroid carcinoma (PTC) and related to more aggressive clinical course of the disease, revealed its significant influence on gene expression profile suggesting that BRAF(+)PTCs represent a molecular subtype of PTC. However, the human material disables distinction of possible molecular causes of cancer from its effects, unlike the mouse model. The main goal of our project was to find genes ...

Introduction: Medullary thyroid carcinoma (MTC) is a malignant thyroid tumor originating from parafollicular C-cells. Most of MTCs (75%) are sporadic while remaining are hereditary. The hereditary form of MTC is a consequence of the mutation of the proto-oncogene RET (Rearranged During Transfection). Somatic mutations of the RET gene are also present in 40%-70% of the sporadic form of MTC (sMTC). Somatic mutations are also observed in the RAS genes and very rarely in the BRAF ...

Introduction: BRAFV600E mutation is the most frequent alteration in papillary thyroid carcinoma (PTC). Although its relation to factors of poor prognosis was demonstrated in many studies the use of BRAF as a predictive marker in clinical treatment of PTC patients is controversial. The aim of our study was to analyze molecular consequences of BRAFV600E mutation in a transgenic mouse model performed for this purpose and to refer the obtained results to...

Introduction: Discovery of V600E (BRAFT1799A) mutation in papillary thyroid carcinoma (PTC) widened our knowledge about mechanisms of its molecular initiation. It has been revealed that activating mutations of the BRAF kinase are much more frequent in PTC than RET rearrangements.Aim of the study: Estimation of V600E BRAF mutation frequency in PTC and analysis of differences in gene expression profile between papillary thyroid car...